59 min ago | Herald Gazette
The June meeting of Keep S'myelin will be held Thursday, June 6, 11:30 a.m. at Kno-Wal-Lin Home Care and Hospice at 170 Pleasant St.
5 hrs ago | Bloomberg
Kari Antin, a 40-year-old financial analyst in Minneapolis, knows she's taking a life-or-death risk with every monthly infusion of Biogen Idec Inc.'s Tysabri.
5 hrs ago | The Moultrie News
Walk More than 100 people came together at Edwards Park for this year's Walk MS: Charleston on May 4. The Greater Carolinas Chapter of the National Multiple Sclerosis Society is excited to announce more than 100 people came together at Edwards Park for this year's Walk MS: Charleston on May 4. Walk MS, presented by Biogen Idec, is an opportunity ... (more)
6 hrs ago | Swindon Advertiser
SWINDON Therapy Centre is encouraging people to take part in the MS Challenge 2013 to help raise money for the centre.
8 hrs ago | Bioscience Technology
Specialty drugmaker Biogen Idec said Tuesday it submitted a new injectable multiple sclerosis drug to the Food and Drug Administration for U.S. market approval.
The centre management team will be fund-raising on Friday, May 31, as part of the MS Society's Cake Break event.
Beaver Creek Resort Co. has selected Can Do MS as the beneficiary of its second annual Cut and Slice Golf Event presented by US Bank, to be held on Monday at the Beaver Creek Golf Club from 11:30 a.m. to 4 p.m. Golfers also will enjoy barbecue and craft beers from Crazy Mountain Brewery and Breckenridge Brewery around the course.
A new Commonwealth grant for researching multiple sclerosis is expected to advance existing research collaborations and enable new ones.
In this video, health-care analyst David Williamson discusses Biogen's latest drug up for FDA approval.
The aetiology of multiple sclerosis remains unknown. This hampers molecular diagnosis and the discovery of bio-molecular markers.
A biologics license application has been submitted to the FDA for approval of Plegridy , a pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis .
Plegridya is Biogen Idec's newly developed subcutaneously administered multiple sclerosis drug therapy and it as just been announced today that it has been submitted to the FDA for the okay to put on the market.
Main Category: Diabetes Also Included In: Immune System / Vaccines ; Multiple Sclerosis ; Arthritis / Rheumatology Article Date: 21 May 2013 - 1:00 PDT Melbourne researchers have identified an immune protein that has the potential to stop or reverse the development of type 1 diabetes in its early stages, before insulin-producing cells have been ... (more)
Multiple sclerosis , a neurological disease that affects millions of people all across the world, harms everyone who has this disease is such unbelievable ways and, as of yet, finding a cure has proved incredibly allusive.
In this video, health-care analyst David Williamson discusses why Biogen Idec 's party may just be getting started despite a huge run in the stock already.